XML 142 R126.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Litigation (Narrative) (Details) £ in Thousands, case in Thousands, € in Millions, $ in Millions |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 17, 2019 patent agreement | Jun. 17, 2019 patent | Sep. 10, 2018 patent | Oct. 24, 2017 patent | Jun. 30, 2017 patent | Feb. 12, 2016 GBP (£) | Jul. 09, 2014 EUR (€) | Feb. 28, 2022 USD ($) | Jun. 19, 2013 EUR (€) | Dec. 31, 2014 USD ($) | Dec. 31, 2021 USD ($) state agreement case increase | Dec. 31, 2021 GBP (£) state case | Apr. 02, 2020 patent
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of cases | case |  |  |  |  |  |  |  |  |  |  | 1 | 1 |
Product Liability |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual |  |  |  |  |  |  |  |  |  |  | $ 74.8 |  |
Intellectual Property |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual |  |  |  |  |  |  |  |  |  |  | $ 226.9 |  |
Number of times damages may be increased in cases of willful infringement | increase |  |  |  |  |  |  |  |  |  |  | 3 |  |
Other Foreign Operations |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual |  |  |  |  |  |  |  |  |  |  | $ 8.4 |  |
MDL |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of states | state |  |  |  |  |  |  |  |  |  |  | 47 | 47 |
Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of states | state |  |  |  |  |  |  |  |  |  |  | 37 | 37 |
Anticompetitive Conduct with Generic Drugs |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of states | state |  |  |  |  |  |  |  |  |  |  | 48 | 48 |
Amended Anticompetitive Conduct with Generic Drugs |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of states | state |  |  |  |  |  |  |  |  |  |  | 43 | 43 |
EU Commission Proceedings Perindorpril | Antitrust Proceedings | Mylan Laboratories Limited |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Damages awarded | € |  |  |  |  |  |  | € 17.2 |  |  |  |  |  |
Loss contingency accrual |  |  |  |  |  |  |  |  |  | $ 21.7 |  |  |
U.K. Competition and Markets Authority Proceedings Paroxetine |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Damages awarded | £ |  |  |  |  |  | £ 5,800 |  |  |  |  |  |  |
Loss Contingency, Damages Awarded On Appeal, Value | £ |  |  |  |  |  | 3,900 |  |  |  |  |  |  |
U.K. Competition and Markets Authority Proceedings Paroxetine | Mylan |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual | £ |  |  |  |  |  |  |  |  |  |  |  | £ 8,800 |
Damages awarded | £ |  |  |  |  |  | 2,700 |  |  |  |  |  |  |
Loss Contingency, Damages Awarded On Appeal, Value | £ |  |  |  |  |  | £ 2,050 |  |  |  |  |  |  |
EU Commission Proceedings Citalopram |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual |  |  |  |  |  |  |  |  |  |  | $ 11.4 |  |
Damages awarded | € |  |  |  |  |  |  |  |  | € 7.8 |  |  |  |
Dimethyl Fumarate |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingency, Patents Allegedly Infringed, Number | patent |  |  |  |  | 6 |  |  |  |  |  |  |  |
Insulin Glargine |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingency, Patents Allegedly Infringed, Number | patent |  |  | 5 | 18 |  |  |  |  |  |  |  |  |
Loss Contingency, Patents Found Not Infringed, Number | 12 | 3 |  |  |  |  |  |  |  |  |  |  |
Loss Contingency, Remaining Claims, Number | patent | 4 | 4 |  | 2 |  |  |  |  |  |  |  |  | 2
Loss Contingency, Other Asserted Patents, Number | patent | 16 | 16 |  |  |  |  |  |  |  |  |  |  |
EpiPen Auto-Injector Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency accrual |  |  |  |  |  |  |  |  |  |  | $ 264.0 |  |
Loss Contingency, Number of States | agreement |  |  |  |  |  |  |  |  |  |  | 17 |  |
EpiPen Auto-Injector Litigation | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Amount awarded to other party |  |  |  |  |  |  |  | $ 264.0 |  |  |  |  |
EpiPen Auto-Injector Litigation | Other current liabilities |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated Litigation Liability |  |  |  |  |  |  |  |  |  |  | $ 274.0 |  |

X
- Definition Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_LitigationReserve
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of loss contingency liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of damages awarded to the plaintiff in the legal matter. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of damages paid to the plaintiff in the legal matter. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_LossContingencyDamagesPaidValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of another entity's patents that the entity has allegedly infringed. + References No definition available. + Details
Name: | us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of another entity's patents that the entity was found not to have infringed. + References No definition available. + Details
Name: | us-gaap_LossContingencyPatentsFoundNotInfringedNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Damages Awarded On Appeal, Value + References No definition available. + Details
Name: | vtrs_LossContingencyDamagesAwardedOnAppealValue
Namespace Prefix: | vtrs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Loss Contingency, Number of States + References No definition available. + Details
Name: | vtrs_LossContingencyNumberOfStates
Namespace Prefix: | vtrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Other Asserted Patents, Number + References No definition available. + Details
Name: | vtrs_LossContingencyOtherAssertedPatentsNumber
Namespace Prefix: | vtrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Remaining Claims, Number + References No definition available. + Details
Name: | vtrs_LossContingencyRemainingClaimsNumber
Namespace Prefix: | vtrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of times damages may be increased in cases of willful infringement + References No definition available. + Details
Name: | vtrs_NumberOfTimesDamagesMayBeIncreasedInCasesOfWillfulInfringement
Namespace Prefix: | vtrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of cases + References No definition available. + Details
Name: | vtrs_Numberofcases
Namespace Prefix: | vtrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of states + References No definition available. + Details
Name: | vtrs_Numberofstates
Namespace Prefix: | vtrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=vtrs_ProductLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=vtrs_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_MultiDistrictLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_AnticompetitiveConductwithDoxycyclineHyclateDelayedReleaseDoxycyclineMonohydrateGlipizideMetforminandVerapamilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_AnticompetitiveConductwithGenericDrugsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_AmendedAnticompetitiveConductwithGenericDrugsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_EUCommissionProceedingsPerindorprilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=vtrs_AntitrustProceedingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_U.K.CompetitionandMarketsAuthorityProceedingsParoxetineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_EUCommissionProceedingsCitalopramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_DimethylFumarateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_InsulinGlargineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_EpiPenAutoInjectorLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |